

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		09724983
	Filing Date		2000-11-28
	First Named Inventor	Scott A. Waldman	
	Art Unit		1642
	Examiner Name	Lei Yao	
Attorney Docket Number		100051.10161	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6040167		2000-03-21	Gluck et al.	
	2	4499080		1985-02-12	Duffot et al.	
	3	4411888		1983-10-25	Klipstein et al.	
	4	5518888		1996-05-21	Waldman	
	5	6087109		2000-07-11	Waldman	
	6	6040147		2000-03-21	Ridker et al.	
	7	5183805		1993-02-02	Lee et al.	
	8	4867973		1989-09-19	Goers et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09724983
Filing Date	2000-11-28
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

9	7097839		2006-08-29	Waldman	
10	4601896		1986-07-22	Nugent	
11	4729893		1988-03-08	Letcher et al.	
12	4849227		1989-07-18	Cho	
13	5271961		1993-12-21	Mathiowitz et al.	
14	5330892		1994-07-19	Vogelstein et al.	
15	5350741		1994-09-27	Takada	
16	5352775		1994-10-04	Albertsen et al.	
17	5399347		1995-03-21	Trentham et al.	
18	4845200		1989-07-04	Cullinan et al.	
19	5057313		1991-10-15	Shih et al.	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number	09724983
Filing Date	2000-11-28
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

20	5166320		1992-11-24	Wu et al.	
21	5585479		1996-12-17	Hoke et al.	
22	5828873		1999-07-27	Waldman	
23	6767704		2004-07-27	Waldman	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

## U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20060269477		1996-11-30	Waldman	
	2	20060014201		2006-01-19	Waldman	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

## FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0341661	EP		1989-11-15	E I Du Pont De Nemours and Company		<input type="checkbox"/>

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	09724983
Filing Date	2000-11-28
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

2	6402700	WO	1984-07-19	Scnpps Clinic and Research Foundation	<input type="checkbox"/>
---	---------	----	------------	---------------------------------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

## NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>9</sup>
	1	Herlyn et al., "Radiomunodetection of human tumor xenografts by monoclonal antibody F(ab') <sub>2</sub> fragments," Nucl Med Biol (1986) 4:401-405.	<input type="checkbox"/>
	2	Lee et al., "Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques," Cancer Research (1990) 50:4546-4551.	<input type="checkbox"/>
	3	Voskogiou-Momiko et al., "Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models," Clinical Cancer Research (2003) 9(11):4227-4239.	<input type="checkbox"/>
	4	Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate. in vitro and in vivo studies," PNAS (1982) 79:626-629.	<input type="checkbox"/>
	5	Cianfrocca et al., "Phase I trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH <sub>2</sub> ), a beta integrin antagonist, in patients with solid tumors," British Journal of Cancer (2006) 1-6.	<input type="checkbox"/>
	6	Russell-Jones, "Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium," Journal of Drug Targeting (2004) 12(2):113-123.	<input type="checkbox"/>
	7	El-Andaloussi et al., "Cell-penetrating peptides: mechanisms and applications," Current Pharmaceutical Design (2005) 11:3597-3611.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09724983
Filing Date	2000-11-28
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

**EXAMINER SIGNATURE**

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.